CA2646400A1 - Formulations pharmaceutiques a peptide apparente au glucagon 1(glp-1) - Google Patents

Formulations pharmaceutiques a peptide apparente au glucagon 1(glp-1) Download PDF

Info

Publication number: CA2646400A1
Authority: CA; Canada
Prior art keywords: glp; fdkp; diketopiperazine; molecule; solution
Prior art date: 2006-04-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA002646400A

Other languages

English (en)

Inventor

Stephanie Greene

David Brandt

Cohava Gelber

Mark King

Wayman Wendell Cheatham

Keith Oberg

Andrea Leone-Bay

Mark J. Hokenson

Mary Faris

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mannkind Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-14

Filing date

2007-04-16

Publication date

2007-10-25

2007-04-16 Application filed by Individual filed Critical Individual

2007-10-25 Publication of CA2646400A1 publication Critical patent/CA2646400A1/fr

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract description 7
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title description 8
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 857
239000000203 mixture Substances 0.000 claims abstract description 148
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims abstract description 140
239000002245 particle Substances 0.000 claims abstract description 132
230000002685 pulmonary effect Effects 0.000 claims abstract description 62
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
201000010099 disease Diseases 0.000 claims abstract description 19
208000008589 Obesity Diseases 0.000 claims abstract description 9
235000020824 obesity Nutrition 0.000 claims abstract description 9
238000000034 method Methods 0.000 claims description 82
239000000843 powder Substances 0.000 claims description 61
108090000765 processed proteins & peptides Proteins 0.000 claims description 56
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 38
230000008569 process Effects 0.000 claims description 38
239000003795 chemical substances by application Substances 0.000 claims description 34
150000003839 salts Chemical class 0.000 claims description 34
239000000725 suspension Substances 0.000 claims description 32
238000011282 treatment Methods 0.000 claims description 28
150000002500 ions Chemical class 0.000 claims description 22
230000000065 osmolyte Effects 0.000 claims description 22
239000004094 surface-active agent Substances 0.000 claims description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
230000001976 improved effect Effects 0.000 claims description 17
230000003285 pharmacodynamic effect Effects 0.000 claims description 16
239000002904 solvent Substances 0.000 claims description 16
230000001851 biosynthetic effect Effects 0.000 claims description 15
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
-1 glutaryl Chemical group 0.000 claims description 11
239000011780 sodium chloride Substances 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
210000004153 islets of langerhan Anatomy 0.000 claims description 7
239000011859 microparticle Substances 0.000 claims description 7
238000004108 freeze drying Methods 0.000 claims description 6
201000001421 hyperglycemia Diseases 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
239000002585 base Substances 0.000 claims description 5
238000001694 spray drying Methods 0.000 claims description 5
208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 4
208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 4
208000032928 Dyslipidaemia Diseases 0.000 claims description 4
208000020358 Learning disease Diseases 0.000 claims description 4
208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
230000001925 catabolic effect Effects 0.000 claims description 4
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims description 4
208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
208000028867 ischemia Diseases 0.000 claims description 4
201000003723 learning disability Diseases 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
230000001172 regenerating effect Effects 0.000 claims description 4
238000001356 surgical procedure Methods 0.000 claims description 4
208000037816 tissue injury Diseases 0.000 claims description 4
125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 3
QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims description 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 48
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 48
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 4
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract description 791
102100040918 Pro-glucagon Human genes 0.000 abstract description 768
238000001727 in vivo Methods 0.000 abstract description 14
238000000338 in vitro Methods 0.000 abstract description 5
206010028980 Neoplasm Diseases 0.000 abstract description 4
BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 description 305
229940094417 fumaryl diketopiperazine Drugs 0.000 description 303
238000009472 formulation Methods 0.000 description 111
230000000694 effects Effects 0.000 description 75
239000000243 solution Substances 0.000 description 70
241001465754 Metazoa Species 0.000 description 52
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 50
241000700159 Rattus Species 0.000 description 43
238000002983 circular dichroism Methods 0.000 description 36
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 35
210000004369 blood Anatomy 0.000 description 35
239000008280 blood Substances 0.000 description 35
238000011068 loading method Methods 0.000 description 35
108091006629 SLC13A2 Proteins 0.000 description 31
210000004027 cell Anatomy 0.000 description 30
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
230000006870 function Effects 0.000 description 27
239000008103 glucose Substances 0.000 description 27
238000001179 sorption measurement Methods 0.000 description 27
102000004877 Insulin Human genes 0.000 description 25
108090001061 Insulin Proteins 0.000 description 25
238000004458 analytical method Methods 0.000 description 25
229940125396 insulin Drugs 0.000 description 25
108010011459 Exenatide Proteins 0.000 description 22
238000002474 experimental method Methods 0.000 description 22
230000036470 plasma concentration Effects 0.000 description 22
241000282693 Cercopithecidae Species 0.000 description 21
229940024606 amino acid Drugs 0.000 description 21
150000001875 compounds Chemical class 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 19
230000015556 catabolic process Effects 0.000 description 19
238000006731 degradation reaction Methods 0.000 description 19
235000012631 food intake Nutrition 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 18
230000037396 body weight Effects 0.000 description 18
210000002966 serum Anatomy 0.000 description 18
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 17
229960001519 exenatide Drugs 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 16
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 16
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 15
230000006907 apoptotic process Effects 0.000 description 14
238000009739 binding Methods 0.000 description 14
238000001556 precipitation Methods 0.000 description 14
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 13
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 13
230000007423 decrease Effects 0.000 description 13
102000004196 processed proteins & peptides Human genes 0.000 description 13
239000000126 substance Substances 0.000 description 13
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 12
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000012530 fluid Substances 0.000 description 12
239000007788 liquid Substances 0.000 description 12
210000004072 lung Anatomy 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 11
231100000607 toxicokinetics Toxicity 0.000 description 11
230000030833 cell death Effects 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 9
238000001802 infusion Methods 0.000 description 9
230000003993 interaction Effects 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
238000004949 mass spectrometry Methods 0.000 description 9
238000005259 measurement Methods 0.000 description 9
210000000496 pancreas Anatomy 0.000 description 9
239000000523 sample Substances 0.000 description 9
238000012916 structural analysis Methods 0.000 description 9
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 8
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
238000013019 agitation Methods 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
230000008859 change Effects 0.000 description 8
230000006240 deamidation Effects 0.000 description 8
230000005284 excitation Effects 0.000 description 8
230000037406 food intake Effects 0.000 description 8
230000003914 insulin secretion Effects 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
230000003647 oxidation Effects 0.000 description 8
238000007254 oxidation reaction Methods 0.000 description 8
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
239000003381 stabilizer Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
238000010521 absorption reaction Methods 0.000 description 7
239000013543 active substance Substances 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
238000007920 subcutaneous administration Methods 0.000 description 7
208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
108010039627 Aprotinin Proteins 0.000 description 6
241000282567 Macaca fascicularis Species 0.000 description 6
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
229960004405 aprotinin Drugs 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
239000003814 drug Substances 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 6
238000010253 intravenous injection Methods 0.000 description 6
238000011084 recovery Methods 0.000 description 6
230000004044 response Effects 0.000 description 6
238000013293 zucker diabetic fatty rat Methods 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 5
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 5
102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
238000001142 circular dichroism spectrum Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000002189 fluorescence spectrum Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
238000007446 glucose tolerance test Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
230000036186 satiety Effects 0.000 description 5
235000019627 satiety Nutrition 0.000 description 5
239000011734 sodium Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
229910001868 water Inorganic materials 0.000 description 5
WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 description 4
108090000672 Annexin A5 Proteins 0.000 description 4
102000004121 Annexin A5 Human genes 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000051325 Glucagon Human genes 0.000 description 4
108060003199 Glucagon Proteins 0.000 description 4
239000004471 Glycine Substances 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 4
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
239000013060 biological fluid Substances 0.000 description 4
238000000423 cell based assay Methods 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
229960004666 glucagon Drugs 0.000 description 4
238000004442 gravimetric analysis Methods 0.000 description 4
229940051250 hexylene glycol Drugs 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
239000000859 incretin Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
235000012054 meals Nutrition 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000007431 microscopic evaluation Methods 0.000 description 4
230000007170 pathology Effects 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
235000011056 potassium acetate Nutrition 0.000 description 4
229910000160 potassium phosphate Inorganic materials 0.000 description 4
235000011009 potassium phosphates Nutrition 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
238000005185 salting out Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
238000013223 sprague-dawley female rat Methods 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000035882 stress Effects 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
231100000041 toxicology testing Toxicity 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 3
102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 3
101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 3
208000013016 Hypoglycemia Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000001174 ascending effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000013281 male obese zucker rat Methods 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
230000008693 nausea Effects 0.000 description 3
230000006654 negative regulation of apoptotic process Effects 0.000 description 3
231100000062 no-observed-adverse-effect level Toxicity 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
239000006174 pH buffer Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000000291 postprandial effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
231100000161 signs of toxicity Toxicity 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
231100001072 toxicokinetic profile Toxicity 0.000 description 3
UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
LBIRTXMKYFJJHM-SNAWJCMRSA-N (e)-4-[4-(3,6-dioxopiperazin-2-yl)butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCCC1NC(=O)CNC1=O LBIRTXMKYFJJHM-SNAWJCMRSA-N 0.000 description 2
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
230000024704 B cell apoptotic process Effects 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
108010058003 Proglucagon Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229960002798 cetrimide Drugs 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
229940124447 delivery agent Drugs 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
230000009228 embryo fetal development Effects 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
108010015174 exendin 3 Proteins 0.000 description 2
LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
210000003020 exocrine pancreas Anatomy 0.000 description 2
230000035558 fertility Effects 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000030136 gastric emptying Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
231100000025 genetic toxicology Toxicity 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002473 insulinotropic effect Effects 0.000 description 2
229940126602 investigational medicinal product Drugs 0.000 description 2
238000009533 lab test Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
208000004731 long QT syndrome Diseases 0.000 description 2
238000007433 macroscopic evaluation Methods 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000000693 micelle Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004001 molecular interaction Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
210000004923 pancreatic tissue Anatomy 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
231100000683 possible toxicity Toxicity 0.000 description 2
230000007542 postnatal development Effects 0.000 description 2
229930010796 primary metabolite Natural products 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229930000044 secondary metabolite Natural products 0.000 description 2
230000011664 signaling Effects 0.000 description 2
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
241000894007 species Species 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
229960001254 vildagliptin Drugs 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
DDGAQLMNFCFXEK-ONEGZZNKSA-N (e)-4-[3-(3,6-dioxopiperazin-2-yl)propylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC1NC(=O)CNC1=O DDGAQLMNFCFXEK-ONEGZZNKSA-N 0.000 description 1
TVUJCFZUAPZEBV-VOTSOKGWSA-N (e)-4-[4-(3,6-dioxo-5-propan-2-ylpiperazin-2-yl)butylamino]-4-oxobut-2-enoic acid Chemical compound CC(C)C1NC(=O)C(CCCCNC(=O)\C=C\C(O)=O)NC1=O TVUJCFZUAPZEBV-VOTSOKGWSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
NUYHTXOPSQBZKC-UHFFFAOYSA-N 3,6-bis(4-aminobutyl)piperazine-2,5-dione Chemical class NCCCCC1NC(=O)C(CCCCN)NC1=O NUYHTXOPSQBZKC-UHFFFAOYSA-N 0.000 description 1
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
101800000112 Acidic peptide Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
241000283707 Capra Species 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241001649081 Dina Species 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
102100023374 Forkhead box protein M1 Human genes 0.000 description 1
108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
102400000325 Glucagon-like peptide 1(7-36) Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
241000270431 Heloderma suspectum Species 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 description 1
NNIVFXCKHNRSRL-VKHMYHEASA-N Hydroxyglutamic acid Chemical compound ON[C@H](C(O)=O)CCC(O)=O NNIVFXCKHNRSRL-VKHMYHEASA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
241000282596 Hylobatidae Species 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229910013470 LiC1 Inorganic materials 0.000 description 1
108010019598 Liraglutide Proteins 0.000 description 1
YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
241000282579 Pan Species 0.000 description 1
241000282520 Papio Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010084214 Peptide PHI Proteins 0.000 description 1
239000000132 Peptide PHI Substances 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091008611 Protein Kinase B Proteins 0.000 description 1
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010074268 Reproductive toxicity Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229940122055 Serine protease inhibitor Drugs 0.000 description 1
101710102218 Serine protease inhibitor Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
238000012288 TUNEL assay Methods 0.000 description 1
206010043275 Teratogenicity Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000036982 action potential Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000036528 appetite Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000003818 area postrema Anatomy 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940084891 byetta Drugs 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
231100000005 chromosome aberration Toxicity 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
238000006074 cyclodimerization reaction Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003158 enteroendocrine cell Anatomy 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000008029 eradication Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
108010024703 exendin (9-39) Proteins 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002907 exocrine cell Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
230000009248 fertility and early embryonic development Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000021472 generally recognized as safe Nutrition 0.000 description 1
230000007674 genetic toxicity Effects 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical group NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
108010069764 helospectin I Proteins 0.000 description 1
HTMVMVKJOPFRMK-OYZAELBCSA-N helospectin i Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 HTMVMVKJOPFRMK-OYZAELBCSA-N 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000036732 histological change Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000000910 hyperinsulinemic effect Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
229940090473 januvia Drugs 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229960002701 liraglutide Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
231100000243 mutagenic effect Toxicity 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000009707 neogenesis Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
238000002577 ophthalmoscopy Methods 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
YLBIOQUUAYXLJJ-WZUUGAJWSA-N peptide histidine methionine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 YLBIOQUUAYXLJJ-WZUUGAJWSA-N 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
230000009237 prenatal development Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
229940124272 protein stabilizer Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
238000009613 pulmonary function test Methods 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003893 regulation of appetite Effects 0.000 description 1
230000009892 regulation of energy homeostasis Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002336 repolarization Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
230000007696 reproductive toxicity Effects 0.000 description 1
231100000372 reproductive toxicity Toxicity 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
235000016491 selenocysteine Nutrition 0.000 description 1
229940055619 selenocysteine Drugs 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229960004034 sitagliptin Drugs 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
210000001679 solitary nucleus Anatomy 0.000 description 1
239000012453 solvate Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
210000001712 subfornical organ Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
231100000211 teratogenicity Toxicity 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000002435 venom Substances 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)

CA002646400A 2006-04-14 2007-04-16 Formulations pharmaceutiques a peptide apparente au glucagon 1(glp-1) Pending CA2646400A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US74488206P	2006-04-14	2006-04-14
US60/744,882		2006-04-14
PCT/US2007/066728 WO2007121411A2 (fr)	2006-04-14	2007-04-16	Formulations pharmaceutiques à peptide apparenté au glucagon 1(glp-1)

Publications (1)

Publication Number	Publication Date
CA2646400A1 true CA2646400A1 (fr)	2007-10-25

Family

ID=38567214

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002646400A Pending CA2646400A1 (fr)	2006-04-14	2007-04-16	Formulations pharmaceutiques a peptide apparente au glucagon 1(glp-1)

Country Status (11)

Country	Link
EP (1)	EP2010155A2 (fr)
JP (3)	JP5415938B2 (fr)
KR (3)	KR101558829B1 (fr)
CN (2)	CN104288756A (fr)
AU (1)	AU2007238000B2 (fr)
BR (1)	BRPI0709964A2 (fr)
CA (1)	CA2646400A1 (fr)
HK (1)	HK1206241A1 (fr)
MX (1)	MX2008013216A (fr)
RU (3)	RU2542500C2 (fr)
WO (1)	WO2007121411A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1808438B1 (fr)	1999-06-29	2014-10-01	MannKind Corporation	Purification et stabilisation de peptide et protéines dans des agents pharmaceutiques
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt)	2004-08-23	2023-01-10	Mannkind Corporation	Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007033372A2 (fr)	2005-09-14	2007-03-22	Mannkind Corporation	Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
DK1986679T3 (da)	2006-02-22	2017-11-20	Mannkind Corp	Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
BRPI0709964A2 (pt) *	2006-04-14	2011-08-02	Mannkind Corp	formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
KR20100090692A (ko) *	2007-10-24	2010-08-16	맨카인드 코포레이션	활성제의 전달
HUE025485T2 (en) *	2007-10-24	2016-02-29	Mannkind Corp	Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
EP2300011A4 (fr)	2008-05-27	2012-06-20	Dmi Life Sciences Inc	Procédés et composés thérapeutiques
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
CA3153292A1 (fr)	2008-06-13	2009-12-17	Mannkind Corporation	Inhalateur de poudre seche et systeme d'administration de medicament
CN102065942B (zh)	2008-06-20	2013-12-11	曼金德公司	用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en)	2009-01-08	2014-12-01	Mannkind Corp	Treatment of hyperglycemia with GLP-1
EP2403490B1 (fr) *	2009-03-04	2019-08-07	MannKind Corporation	Système amélioré pour la délivrance d'un médicament sous la forme d'une poudre sèche
PL2405963T3 (pl)	2009-03-11	2014-04-30	Mannkind Corp	Urządzenie, układ i sposób pomiaru oporu inhalatora
BRPI1010722B1 (pt)	2009-06-12	2019-12-10	Mannkind Corp	micropartículas de dicetopiperazina com teores de isômero definidos, pó seco, uso de uma formulação de pó seco compreendendo micropartículas de dicetopiperazina, método de preparar micropartículas e método para sintetizar uma dicetopiperazina
KR20180036807A (ko)	2009-06-12	2018-04-09	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2482840A4 (fr) *	2009-08-07	2013-06-26	Mannkind Corp	Composition glp-1 val (8) et procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable
CA2778698A1 (fr)	2009-11-03	2011-05-12	Mannkind Corporation	Appareil et methode de simulation d'efforts d'inhalation
RU2571331C1 (ru)	2010-06-21	2015-12-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
JP2013537195A (ja)	2010-09-07	2013-09-30	ディエムアイアクイジションコーポレイション	疾患の治療
KR101940832B1 (ko)	2011-04-01	2019-01-21	맨카인드 코포레이션	의약 카트리지용 블리스터 패키지
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
AU2012323320B2 (en)	2011-10-10	2017-05-11	Ampio Pharmaceuticals, Inc.	Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2766029B1 (fr)	2011-10-10	2020-03-25	Ampio Pharmaceuticals, Inc.	Traitement de maladie dégénérative articulaire
EP2776053A1 (fr)	2011-10-24	2014-09-17	MannKind Corporation	Procédés et compositions pour traiter la douleur
AU2012328605B9 (en)	2011-10-28	2017-08-03	Ampio Pharmaceuticals, Inc.	Treatment of rhinitis
ES3041720T3 (en)	2012-07-01	2025-11-14	Novo Nordisk As	Use of long-acting glp-1 peptides
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
BR112015004418A2 (pt) *	2012-08-29	2017-07-04	Mannkind Corp	composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit.
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911690A1 (fr)	2012-10-26	2015-09-02	MannKind Corporation	Compositions et procédés de vaccin antigrippal inhalable
HRP20181300T1 (hr)	2012-12-21	2018-10-05	Sanofi	Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
AU2014228415B2 (en) *	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
WO2014145729A2 (fr)	2013-03-15	2014-09-18	Ampio Pharmaceuticals, Inc.	Compositions pour la mobilisation, l'écotropisme, l'expansion et la différenciation de cellules souches et leurs méthodes d'utilisation
CA2918369C (fr) *	2013-07-18	2021-06-29	Mannkind Corporation	Compositions pharmaceutiques en poudre seche stables a la chaleur et procedes
WO2015021064A1 (fr)	2013-08-05	2015-02-12	Mannkind Corporation	Appareil d'insufflation et procédés
US9782344B2 (en)	2013-08-22	2017-10-10	Zp Opco, Inc.	Stable glucagon peptide formulations
US9173924B2 (en)	2013-08-22	2015-11-03	Zp Opco, Inc.	Stable glucagon peptide formulations
EP3080149A1 (fr)	2013-12-13	2016-10-19	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
EP3080154B1 (fr)	2013-12-13	2018-02-07	Sanofi	Agonistes doubles du récepteur glp-1/gip
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3062772B1 (fr) *	2014-03-18	2018-01-24	APEPTICO Forschung und Entwicklung GmbH	Médicament peptidique sous forme de poudre sèche
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
JP6723222B2 (ja)	2014-08-18	2020-07-15	アンピオファーマシューティカルズ，インコーポレイテッド	関節病態の治療
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016209969A1 (fr)	2015-06-22	2016-12-29	Ampio Pharmaceuticals, Inc.	Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN108066762B (zh) *	2016-11-07	2022-04-01	赫兰	Glp-1受体激动剂类药物的用途
IL322969A (en)	2017-10-12	2025-10-01	Novo Nordisk As	Semaglutide in medical therapy
TWI705820B (zh) *	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
CN109827875A (zh) *	2019-04-10	2019-05-31	上海市食品药品检验所	一种用于测定吸入制剂溶出度的装置和方法
KR20210062509A (ko)	2019-11-21	2021-05-31	대한민국(전북기계공업고등학교장)	필터리스 다이나믹 미세먼지 공기 청정기
CN115192554A (zh) *	2022-08-08	2022-10-18	浙江仙琚萃泽医药科技有限公司	无抛射剂的含肽吸入溶液剂及其制备方法
WO2025159538A1 (fr) *	2024-01-26	2025-07-31	주식회사 아울바이오	Microsphères comprenant des peptides à base de glp-1 ra, leur procédé de préparation et composition pharmaceutique les comprenant
KR20250152464A (ko)	2024-04-16	2025-10-23	한미약품 주식회사	흡입제 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5352461A (en) *	1992-03-11	1994-10-04	Pharmaceutical Discovery Corporation	Self assembling diketopiperazine drug delivery system
DE4242863A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
WO1999014239A1 (fr) *	1997-09-12	1999-03-25	Wolf Georg Forssmann	Composition pour le traitement du diabete sucre et de l'obesite
EP1808438B1 (fr) *	1999-06-29	2014-10-01	MannKind Corporation	Purification et stabilisation de peptide et protéines dans des agents pharmaceutiques
EP1542712A2 (fr) *	2001-06-01	2005-06-22	Eli Lilly And Company	Formulations de glp-1 a action etalee dans le temps
MXPA04008068A (es) *	2002-02-20	2004-11-26	Lilly Co Eli	Metodo para administrar moleculas de glp-1.
WO2003075834A2 (fr) *	2002-03-08	2003-09-18	Eli Lilly And Company	Formulations de proteines c activees
US20040038865A1 (en) *	2002-08-01	2004-02-26	Mannkind Corporation	Cell transport compositions and uses thereof
CA2493478C (fr) *	2002-08-01	2014-11-18	Mannkind Corporation	Compositions de transport cellulaire et utilisations
CA2528007C (fr) *	2003-06-02	2012-03-27	Chiron Corporation	Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
BR122019022692B1 (pt) *	2004-08-23	2023-01-10	Mannkind Corporation	Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007033372A2 (fr) *	2005-09-14	2007-03-22	Mannkind Corporation	Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
DK1986679T3 (da) *	2006-02-22	2017-11-20	Mannkind Corp	Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
BRPI0709964A2 (pt) *	2006-04-14	2011-08-02	Mannkind Corp	formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)

2007
- 2007-04-16 BR BRPI0709964-9A patent/BRPI0709964A2/pt not_active IP Right Cessation
- 2007-04-16 KR KR1020147011316A patent/KR101558829B1/ko active Active
- 2007-04-16 RU RU2010137392/15A patent/RU2542500C2/ru not_active IP Right Cessation
- 2007-04-16 JP JP2009505655A patent/JP5415938B2/ja not_active Expired - Fee Related
- 2007-04-16 KR KR1020157008571A patent/KR20150042304A/ko not_active Ceased
- 2007-04-16 CN CN201410514033.8A patent/CN104288756A/zh active Pending
- 2007-04-16 KR KR1020087027774A patent/KR101438839B1/ko active Active
- 2007-04-16 CA CA002646400A patent/CA2646400A1/fr active Pending
- 2007-04-16 MX MX2008013216A patent/MX2008013216A/es active IP Right Grant
- 2007-04-16 RU RU2008144965/15A patent/RU2409349C2/ru not_active IP Right Cessation
- 2007-04-16 EP EP20070760728 patent/EP2010155A2/fr not_active Withdrawn
- 2007-04-16 CN CNA200780013424XA patent/CN101453988A/zh active Pending
- 2007-04-16 WO PCT/US2007/066728 patent/WO2007121411A2/fr not_active Ceased
- 2007-04-16 AU AU2007238000A patent/AU2007238000B2/en not_active Ceased
2013
- 2013-09-17 JP JP2013191549A patent/JP5898156B2/ja active Active
2014
- 2014-12-23 RU RU2014152320A patent/RU2014152320A/ru not_active Application Discontinuation
2015
- 2015-07-16 HK HK15106772.4A patent/HK1206241A1/xx unknown
- 2015-11-30 JP JP2015233125A patent/JP2016104736A/ja active Pending

Also Published As

Publication number	Publication date
CN104288756A (zh)	2015-01-21
RU2542500C2 (ru)	2015-02-20
AU2007238000B2 (en)	2013-01-17
KR101438839B1 (ko)	2014-10-02
HK1206241A1 (en)	2016-01-08
JP5415938B2 (ja)	2014-02-12
RU2409349C2 (ru)	2011-01-20
WO2007121411A2 (fr)	2007-10-25
JP2016104736A (ja)	2016-06-09
KR20080111533A (ko)	2008-12-23
JP2009533476A (ja)	2009-09-17
JP5898156B2 (ja)	2016-04-06
CN101453988A (zh)	2009-06-10
RU2008144965A (ru)	2010-05-20
KR101558829B1 (ko)	2015-10-08
JP2014043445A (ja)	2014-03-13
EP2010155A2 (fr)	2009-01-07
MX2008013216A (es)	2008-10-27
KR20150042304A (ko)	2015-04-20
WO2007121411A3 (fr)	2007-12-13
KR20140072138A (ko)	2014-06-12
BRPI0709964A2 (pt)	2011-08-02
AU2007238000A1 (en)	2007-10-25
RU2010137392A (ru)	2012-03-20
RU2014152320A (ru)	2016-07-20

Publication	Publication Date	Title
AU2007238000B2 (en)	2013-01-17	Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
US20080260838A1 (en)	2008-10-23	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
EP1478233B1 (fr)	2016-11-09	Methode d'administration de molecules peptidiques du type glucagon (glp-1)
EP1060191B1 (fr)	2010-04-28	Derives d'analogues de glp-1
JP5918539B2 (ja)	2016-05-18	Ｇｌｐ−１を用いる高血糖症の治療方法
US8642548B2 (en)	2014-02-04	Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
EP3295952B1 (fr)	2021-02-17	Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
KR20170073638A (ko)	2017-06-28	글루카곤 및 glp-1 수용체의 공-효능제
US20140066370A1 (en)	2014-03-06	Polypeptide Conjugate
AU2013201640A1 (en)	2013-04-11	Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
US11028137B2 (en)	2021-06-08	Mutant islet amyloid polypeptides with improved solubility and methods for using the same
HK1133383A (en)	2010-03-26	Glucagon-like peptide 1(glp-1) pharmaceutical formulations
HK40070502B (zh)	2024-06-07	胰岛素衍生物
HK1166449B (en)	2018-06-15	Method for administering glp-1 molecules
HK1166449A (en)	2012-11-02	Method for administering glp-1 molecules

Legal Events

Date	Code	Title	Description
2012-01-19	EEER	Examination request
2016-10-23	EEER	Examination request	Effective date: 20120119